Trexquant Investment LP Larimar Therapeutics, Inc. Transaction History

Trexquant Investment LP

  • $8.9 Billion
  • Q3 2025

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
SELL
$3.8 - $9.29 $106,555 - $260,500
-28,041 Reduced 18.56%
123,066 $470,000
Q3 2024

Nov 12, 2024
SELL
$6.3 - $10.68 $220,922 - $374,515
-35,067 Reduced 18.84%
151,107 $989,000
Q2 2024

Aug 13, 2024
BUY
$6.33 - $9.89 $886,073 - $1.38 Million
139,980 Added 303.03%
186,174 $1.35 Million
Q1 2024

May 14, 2024
BUY
$4.2 - $13.28 $194,014 - $613,456
46,194 New
46,194 $350,000
Q1 2023

May 15, 2023
BUY
$4.0 - $6.68 $138,412 - $231,148
34,603 New
34,603 $156,000

Others Institutions Holding LRMR

# of Institutions
155
Shares Held
89M
Call Options Held
6.44M
Put Options Held
622K
View Full List

About Larimar Therapeutics, Inc.

LRMR Quotes by TradingView
  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $146M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email